Literature DB >> 16401470

Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome.

Patricia Wong1, Sigitas J Verselis, Judy E Garber, Katherine Schneider, Lisa DiGianni, David H Stockwell, Frederick P Li, Sapna Syngal.   

Abstract

BACKGROUND & AIMS: Hereditary colorectal cancer is associated most commonly with the hereditary nonpolyposis colorectal cancer or familial adenomatous polyposis syndromes. We investigated the prevalence of early onset colorectal cancer and the frequency of p53 germline mutations in 64 families from a Li-Fraumeni syndrome (LFS) registry.
METHODS: Patients with documented colorectal cancer and a diagnosis at or before age 50 were included. P53 analyses were performed through germline mutational analyses using standard molecular techniques.
RESULTS: Among the 397 patients and 64 families in the classic LFS registry, a total of 11 patients (2.8%) from 10 different families (15.6%) met criteria for classic LFS and had documented colorectal cancer at less than 50 years of age. The mean age at diagnosis in this group was 33 years and of these patients 4 developed colorectal cancer before age 21 (ages, 9, 11, 15, and 20 y). All families that were tested for p53 mutations (8 of 10) had evidence of germline mutations by sequence analysis; therefore, 12.5% of the total number of families in the registry had colorectal cancer at age less than 50 years and a documented germline p53 mutation. Mutations primarily were missense or nonsense and were located between exons 4-10.
CONCLUSIONS: LFS patients with germline p53 mutations may have an increased susceptibility to colorectal cancer and present up to several decades earlier than the general population. LFS should be considered when a young patient presents with colorectal cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16401470     DOI: 10.1053/j.gastro.2005.10.014

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  38 in total

1.  p53 protein regulates Hsp90 ATPase activity and thereby Wnt signaling by modulating Aha1 expression.

Authors:  Sachiyo Okayama; Levy Kopelovich; Gabriel Balmus; Robert S Weiss; Brittney-Shea Herbert; Andrew J Dannenberg; Kotha Subbaramaiah
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

2.  Next generation sequencing is informing phenotype: a TP53 example.

Authors:  R O'Shea; R Clarke; E Berkley; C Giffney; M Farrell; E O'Donovan; D J Gallagher
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

3.  Colon Pathology Characteristics in Li-Fraumeni Syndrome.

Authors:  William Rengifo-Cam; Hailey M Shepherd; Kory W Jasperson; N Jewel Samadder; Wade Samowitz; Sheryl R Tripp; Joshua D Schiffman; Wendy Kohlmann
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-15       Impact factor: 11.382

Review 4.  Clinical management of hereditary breast cancer syndromes.

Authors:  Amy S Clark; Susan M Domchek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-01       Impact factor: 2.673

Review 5.  Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53.

Authors:  Alessandra Ferrarini; Agnes Auteri-Kaczmarek; Alessia Pica; Nemya Boesch; Karl Heinimann; Stephan C Schäfer; Sara Vesnaver-Megalo; Viviane Cina; Jacques S Beckmann; Christian Monnerat
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

6.  Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Authors:  Michelle G Rath; Serena Masciari; Rebecca Gelman; Alexander Miron; Penelope Miron; Kathleen Foley; Andrea L Richardson; Ian E Krop; Sigitas J Verselis; Deborah A Dillon; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2013-04-12       Impact factor: 4.872

7.  Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer.

Authors:  Sajid A Khan; Kamran Idrees; Ann Forslund; Zhaoshi Zeng; Shoshana Rosenberg; Hanna Pincas; Francis Barany; Kenneth Offit; Michael P Laquaglia; Philip B Paty
Journal:  J Surg Oncol       Date:  2008-06-01       Impact factor: 3.454

Review 8.  The molecular biology of gastrointestinal cancer: implications for diagnosis and therapy.

Authors:  C Richard Boland
Journal:  Gastrointest Endosc Clin N Am       Date:  2008-07

Review 9.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

10.  Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome.

Authors:  Bryson W Katona; Jacquelyn Powers; Danielle B McKenna; Jessica M Long; Anh N Le; Ryan Hausler; Kristin Zelley; Sarah Jennings; Susan M Domchek; Katherine L Nathanson; Suzanne P MacFarland; Kara N Maxwell
Journal:  Am J Gastroenterol       Date:  2020-12       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.